Sensorion

Back to previous page

Identification

ALSEN
Name: Sensorion
Market: Euronext Growth Paris
Subsector: Biotechnology
Isin code: FR0012596468
Symbol: ALSEN

Operation

IPO Date: 21/04/2015
Issue type: Initial Public offering
Price range: EUR 4.54 - EUR 6.12

Company Profile

Loading... Please wait.

News

Date Title
21 Apr 2015 Sensorion lists on Alternext Paris expand

Raises €8.2 million, market capitalisation totals €23 million

Paris – 21 April 2015–EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs[1],today congratulated Sensorion, a biotech company specialising in the treatment of pathologies of the inner ear, on its successful listing on Alternext in Paris.

Sensorion was spun off from Inserm, the French institute of health and medical research, in 2009 and is based in Montpellier in southern France. It focuses on all types of severe inner ear pathologies, affecting balance and hearing, and is developing three drug candidate programs for medical needs that remain untreated to date. The company has devised a full technology platform that allows it to identify and test the most promising drug candidates for all severe inner ear disorders, both symptomatic and anti-lesional. It plans to become a leading player in treating these pathologies.

Sensorion (ticker symbol: ALSEN) was listed through the admission to trading of 5,078,990 ordinary shares, including 1,816,100 new shares issued under a Global Offering[2].

The admission price and issue price of Sensorion was set at €4.54 per share. Market capitalisation on the day of listing was €23 million, and the operation raised a total of €8.2 million

Sensorion CEO Laurent Nguyen said: “We are delighted to list on Alternext in Paris. And we want to thank all of our shareholders—old and new—for helping us achieve this milestone and for accompanying us on the road to future growth. Thanks to their support and the hard work of our teams, we have every intention of rapidly becoming a major player in the treatment of inner ear pathologies.”

Eric Forest, Chairman and CEO of EnterNext, said “We are very pleased to welcome Sensorion, an innovative company from the Languedoc-Roussilon region, to Alternext. Listing should enable it to step up the pace of its product development. Today EnterNext is working with nearly 70 companies in the life sciences, representing total market capitalisation of over €11 billion. We believe that our initiatives in support of technology companies will strengthen our positioning in tech shares in Europe.”



[1]Small and medium-size companies
[2]
TheGlobal Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries

 

21 Apr 2015 Sensorion expand

EnterNext welcomes Sensorion on Alternext in Paris

Laurent Nguyen, CEO of Sensorion, rings the opening bell.

Sensorion specializes in the research and development of medicines for the treatment of inner ear disorders (dizziness or loss of balance, hearing problems, tinnitus, etc.).

The company has three products in its portfolio, all in the final phases of pre-clinical development.